Four months after Jeff Huber stepped down as CEO of GRAIL, the company has tapped his replacement. Source: BioSpace

Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace

Ginkgo Bioworks, recently recognized by Forbes as one of 25 U.S. companies likely to hit a valuation of $1B or more, is well on its way. Source: BioSpace

As part of the licence agreement, Takeda has taken a strategic equity stake in Izana. Source: BioSpace

reMYND's pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk. Source: BioSpace

Reportedly, Raze Therapeutics, a biotech launched in 2014, has closed its doors. Source: BioSpace

The round was led by BVF Partners, with new investors GV, Casdin Capital, EcoR1 Capital and Section 32. Source: BioSpace

The companies will also collaborate on discovery efforts to identify additional compounds from Ono’s PGE2 receptor antagonist programs. Source: BioSpace

Investors were Atlas Venture and OrbiMed. Source: BioSpace

Harpoon's former CEO also hinted at possible growth at the office, including new hires for engineering and clinical team members. Source: BioSpace